Compare CLBT & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLBT | BEAM |
|---|---|---|
| Founded | 1999 | 2017 |
| Country | Israel | United States |
| Employees | 1285 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.0B |
| IPO Year | N/A | 2019 |
| Metric | CLBT | BEAM |
|---|---|---|
| Price | $13.70 | $30.26 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 12 |
| Target Price | $22.50 | ★ $50.75 |
| AVG Volume (30 Days) | 1.7M | ★ 2.0M |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 82.31 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $24,000.00 |
| Revenue This Year | $21.45 | N/A |
| Revenue Next Year | $17.47 | $33.77 |
| P/E Ratio | $45.29 | ★ N/A |
| Revenue Growth | N/A | ★ 33.33 |
| 52 Week Low | $11.03 | $15.52 |
| 52 Week High | $19.98 | $36.44 |
| Indicator | CLBT | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 55.80 | 56.47 |
| Support Level | $13.01 | $25.84 |
| Resistance Level | $13.78 | $32.01 |
| Average True Range (ATR) | 0.51 | 1.85 |
| MACD | 0.13 | -0.03 |
| Stochastic Oscillator | 83.21 | 58.65 |
Cellebrite DI Ltd provides AI-powered digital investigative and intelligence solutions that help public and private sector customers transform investigative workflows, make digital data more accessible and actionable, and improve the efficiency of mobile research and application security. Its solutions support law enforcement, defense, and intelligence agencies in advancing investigations, border security, counterterrorism, intelligence operations, and cyber operations. The company's software also enables enterprises and service providers to collect and review data for corporate investigations, eDiscovery, incident response, and mobile application validation. It operates in the Americas, APAC, and EMEA, with the majority of revenue from the Americas.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.